within Pharmacolibrary.Drugs.ATC.G;

model G03XC01
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.02,
    Cl             = 0.000735,
    adminDuration  = 600,
    adminMass      = 60 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 2.34,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0014333333333333331,
    Tlag           = 600,            
    Vdp             = 1.73,
    k12             = 365,
    k21             = 365
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>G03XC01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Raloxifene is a selective estrogen receptor modulator (SERM) used primarily for the prevention and treatment of osteoporosis in postmenopausal women. It is also indicated for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis or at high risk for invasive breast cancer. Raloxifene is currently approved and in therapeutic use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy postmenopausal women after oral administration.</p><h4>References</h4><ol><li><p>Murthy, A, et al., &amp; Vats, R (2020). Self-assembled lecithin-chitosan nanoparticles improve the oral bioavailability and alter the pharmacokinetics of raloxifene. <i>International journal of pharmaceutics</i> 588 119731–None. DOI:<a href=&quot;https://doi.org/10.1016/j.ijpharm.2020.119731&quot;>10.1016/j.ijpharm.2020.119731</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32763388/&quot;>https://pubmed.ncbi.nlm.nih.gov/32763388</a></p></li><li><p>Snyder, KR, et al., &amp; Malinowski, JM (2000). Raloxifene hydrochloride. <i>American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists</i> 57(18) 1669–1678. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11006795/&quot;>https://pubmed.ncbi.nlm.nih.gov/11006795</a></p></li><li><p>Wempe, MF, et al., &amp; Buchanan, CM (2008). Pharmacokinetics of raloxifene in male Wistar-Hannover rats: influence of complexation with hydroxybutenyl-beta-cyclodextrin. <i>International journal of pharmaceutics</i> 346(1-2) 25–37. DOI:<a href=&quot;https://doi.org/10.1016/j.ijpharm.2007.06.002&quot;>10.1016/j.ijpharm.2007.06.002</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17644287/&quot;>https://pubmed.ncbi.nlm.nih.gov/17644287</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end G03XC01;
